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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.02.041Objective: The presence of the glycoprotein IIIa allele PlA2 is associated with
enhanced thrombin formation and an impaired antithrombotic action of aspirin,
which could favor coronary thrombosis. We wondered whether PlA1/A2 genetic
polymorphism could affect the postoperative bleeding in patients undergoing cor-
onary artery bypass grafting. We also aimed to assess the effects of aspirin
pretreatment and to ascertain the value of platelet function studies as predictors of
postoperative bleeding.
Methods: In a randomized, double-blind study, patients undergoing coronary artery
bypass grafting were pretreated with a 150-mg dose of aspirin orally 12 and 3 hours
before surgery (n  51, 41 elective) or with placebo (n  51, 43 elective). The
hemostasis was monitored by Simplate (bioMérieux, Inc, Durham, NC) bleeding
time and capillary closure time (platelet function analyzer PFA 100; Sysmex UK
Ltd, Milton Keynes, United Kingdom). Postoperative bleeding and blood products
transfusions were recorded. The glycoprotein IIIa polymorphism was analyzed.
Results: Bleeding was significantly greater in PlA1 homozygotes from control group.
Blood loss was significantly greater (by 25%) in aspirin group. The volume of blood
products transfusions in aspirin patients was significantly larger (by 137%). When
subjects were stratified accordingly to blood platelet glycoprotein IIb/IIIa genotype,
in the aspirin group PlA2 carriers had greater blood loss than PlA1 homozygotes
(1858  932 mL vs 1216  525 mL, P  .05).
Conclusion: PlA1 homozygotes normally had a greater risk of perioperative bleed-
ing. Capillary closure time had no advantage relative to Simplate bleeding time in
predicting postoperative blood loss. Aspirin pretreatment revealed no beneficial
effects and resulted in increased postoperative bleeding and requirement for blood
product transfusions after coronary artery bypass grafting in patients with stable
angina. It was most unfavorable for PlA2 carriers.
Aspirin is a widely established drug in the treatment of coronary arterydisease. It has been proved to decrease the risk of cardiovascular events,especially in coronary artery disease. According to the American College of
Cardiology and the American Heart Association, it should be used by every patient
at risk for coronary artery disease unless there are specific contraindications.
The benefits of an early introduction of aspirin after coronary artery bypass
grafting (CABG) have been well documented. The recent American College of
Cardiology and American Heart Association Practice Guidelines for CABG1
strongly recommend aspirin as a drug of choice against early vein graft closure in
the first postoperative year2,3 and advice its introduction in the first 6 hours after the
surgery because it reduces risk of myocardial infarction, stroke, renal failure, and
bowel infarction.4 Early postoperative introduction of aspirin is associated with
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fore is now a criterion standard and should be administered
routinely shortly after surgery.
In contrast, aspirin administered before surgery increases
the postoperative blood loss because of its antiplatelet ac-
tion.6 It is also associated with increased risk of transfusion,
reexploration for bleeding, and prolonged wound healing
time.1 However, there are some data suggesting that this is
not true for all patients.7-9 Thus some patients could prob-
ably benefit from preoperative use of aspirin also.10,11
If possible, aspirin should be stopped 7 to 10 days before
the surgery, and this is often a problem. Many patients with
acute coronary syndromes receive aspirin because its ben-
efits outweigh the risk of postoperative bleeding. If an
urgent operation is required, it is not possible to withdraw
the aspirin.
The emerging data point to an important role of platelets
early after CABG, separate and distinct from their contrib-
uting role in long-term patency of grafts. The formation of
occlusive platelet aggregates involves the cross-linking of
activated glycoprotein IIb/IIIa receptors on adjacent plate-
lets by fibrinogen and other macromolecular ligands. A
single nucleotide transition at position 1565 in exon 2 of the
gene encoding glycoprotein IIIa leads to its diallelic poly-
morphism (PlA1/A2). PlA2 is present in 20% to 30% of the
white population and is associated with enhanced thrombin
formation and an impaired antithrombotic action of aspirin,
which might favor coronary thrombosis in PlA2 carriers.
This study was based on two hypotheses, that PlA1/A2
polymorphism influences bleeding after CABG and that
platelet function studies have predictive value for perioper-
ative blood loss in patients who were taking aspirin when
they were operated on.
Patients and Methods
The randomized, double-blind study included two groups with a
total of 102 patients with coronary artery disease referred for
CABG. The vast majority of cases were elective (80.4% vs 84.3%,
aspirin vs control group, respectively). Ten patients in the aspirin
group and 8 in the control group underwent operation on an urgent
basis, and they were treated with preoperative intravenous nitro-
glycerin and heparin. Patients were assigned to the treatment
groups (aspirin vs control) with a computer pseudorandom number
generator. Odd and even numbers were used to assign aspirin and
placebo, respectively, and the study team was not aware of the
number assigned. After completion of the study, the numbers were
decoded and the patients were analyzed according to treatment
(aspirin or placebo). The study medication was prepared in the
pharmacology department of our center. None of the patients was
treated with any antiplatelet agents for 10 days before the opera-
tion. In the first group, patients (n  51) received 150 mg aspirin
12 hours and 3 hours before surgery; patients from the second
group (n  51) received placebo. The study was approved by the
university ethics committee, and all patients gave informed con-
sent to participate.
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sternotomy, cardiopulmonary bypass (CPB), moderate hypother-
mia (28°C), and blood cardioplegia were used. Intravenous heparin
was administered (300 U/kg) before ascending aorta cannulation.
Additional doses of heparin (100 U/kg) were given after 60 min-
utes of CPB. Activated clotting time (ACT) was kept at greater
than 480 seconds. Once the patient was weaned from CPB, pro-
tamine sulfate (3 mg/kg) was given to reverse the anticoagulant
action of heparin. If a patient required mechanical support (intra-
aortic balloon pump), additional doses of intravenous heparin were
given to maintain ACT at the level of 180 to 200 seconds. In such
instances, no reversal treatment (protamine sulfate) was adminis-
tered unless the patient had excessive bleeding.
Patient demographic data (sex, age, weight, height), medical
history (history of stroke, hypertension, diabetes, chronic obstruc-
tive pulmonary disease, renal failure, or peripheral artery disease
and Canadian Cardiovascular Society and New York Heart Asso-
ciation functional classes) were obtained before the operation.
During and after the operation, CPB time, crossclamp time,
number of grafts, use of left internal thoracic artery, need for
inotropes (dopamine, epinephrine), and mechanical (intra-aortic
balloon pump) support were recorded. Serum levels of creatinine
kinase and its heart fraction (CK-MB) and troponin I were mon-
itored and recorded before the operation and on days 0, 1, and 3.
When the previously mentioned markers were elevated, they were
assessed during another 2 consecutive days. Electrocardiography
(ECG) was recorded during admission, on the day of the operation,
and on postoperative days 0, 1, 3, and 7. Perioperative myocardial
infarction was diagnosed when one of the following was observed:
new Q wave in ECG, CK-MB greater than 50 U with ECG
changes, or 4-fold increase in CK-MB level independent of ECG
changes. The need for reexploration for bleeding (differentiation
between surgical bleeding and oozing), postoperative renal failure
(postoperative serum creatinine level 2.0 mg/dL or elevation of
50% over baseline), infections (deep sternal site infection), need
for prolonged mechanical ventilation (more than 3 days according
to the analysis performed by Branca and colleagues12), length of
stay in the intensive care unit (ICU), length of hospitalization, and
deaths were recorded.
Before and after the operation (days 0, 1, 3, and 7), whole blood
cell count was recorded. After operation, immediately after trans-
fer of the patient to the ICU, and 24 hours later, Simplate R
(bioMérieux, Inc, Durham, NC) bleeding time was measured.
Before the operation, 10 and 30 minutes after establishment of
CPB, after transfer of the patient to the ICU and 24 hours after
surgery, closure time was measured with the PFA-100 analyzer
(Sysmex UK Ltd, Milton Keynes, United Kingdom). This is an ex
vivo study in which whole blood is sucked into capillary tube. The
high shear-stress rate causes platelet activation and aggregation.
Two types of membranes are used, coated with epinephrine and
collagen and with adenosine and collagen, both potent platelet
activating agents. The analyzer measures the time in which blood
clots inside the capillary tube (closure time).13
The glycoprotein IIIa polymorphism was analyzed after the
operation. Genomic DNA samples were obtained by standard
methods from peripheral blood leukocytes of the subjects studied.
DNA concentration was quantified with spectrophotometry. A
282–base pair fragment from exon 2 and intron 2 of the glyco-
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ers by using polymerase chain reaction. Reaction products were
digested with MspI restriction endonuclease, and 125– and 157–
base pair fragments were seen only if PlA2 allele was present
because of the MspI restriction enzyme cutting site at the thymine
to cytosine replacement. Genotypes were scored on 1.5% agarose
gel (SFR Agarose; Amresco, Solon, Ohio) and stained with
0.5g/mL ethidium bromide under a UV transilluminator.
Intraoperative blood loss was measured by quantifying the
amount of blood in the external suction reservoir and by weighing
the swabs. Postoperative blood loss was recorded as the volume of
chest tube drainage connected to at four-chamber Sherwood col-
lection bag that was kept under suction of 15 mm H2O for the
first 12 hours after the operation.
A hemoglobin level below 8.0 g/dL was the threshold for blood
transfusion. The numbers of units transfused of packed red blood
cells, fresh-frozen plasma, and platelets was recorded. No antifi-
brinolytic agents (-aminocaproic acid, tranexamic acid) or serine
protease inhibitors (aprotinin) were used in the study.
Platelet count, prothrombin time, and ACT were measured
directly after transfer of the patient to the ICU. If ACT was
elevated, an additional dose of protamine sulfate was administered.
In case of elevated prothrombin time, patient was treated with
fresh-frozen plasma (10-15 mL/kg). If excessive bleeding persisted
or platelet count was less than 80,000 cells/L after correction of
these clotting abnormalities, platelet transfusion was done. The
dose of platelet concentrate was individually calculated for every
patient by the blood bank. The calculations were based on body
weight, height, and platelet count. From the first postoperative day
on, 150 mg of aspirin was administered orally.
Statistical Analysis
Statistical evaluation was performed with a personal computer and
Statistica 5.5 software (StatSoft Inc, Tulsa, Okla). Summary sta-
tistics were expressed as means and SDs or 95% confidence
intervals. The general linear model, including analysis of variance
(the Kolomogorov-Smirnov variant) and multivariate analysis of
variance, was used. The 2 approach for testing Hardy-Weinberg
equilibrium was used for genotype frequency analysis and for
comparison of polymorphism frequency between the groups
studied.
Results
We studied 102 subjects, 51 study patients who received
aspirin preoperatively and 51 control patients who did not
received the drug before CABG. Preoperative patient char-
acteristics are presented in Table 1, and data related to
CABG procedure are presented in Table 2. Three patients
died in the early postoperative period, 2 in the study group
and 1 in the control group. One patient in the aspirin group
died of sepsis and multiorgan failure and the other of
pneumonia, renal insufficiency, and congestive heart fail-
ure. One patient in the control group died of perioperative
myocardial infarction resistant to pharmacologic and me-
chanical (intra-aortic balloon pump) support. Two patients
in the control group and 4 in the aspirin group required
reexploration for bleeding (P  .674). In all cases, the
The Journal of Thoracibleeding site was identified and surgically controlled. Eigh-
teen patients in the aspirin group and 4 in the control group
received platelet concentrate postoperatively (P  .0129)
PlA1/A2 polymorphism was ascertained in 51 patients in
the aspirin group and in 51 control patients; in 3 cases, no
DNA was available for genotyping. In the aspirin group,
frequency of the PlA2 allele was 10.8%: 7 subjects were
heterozygotic (PlA1/A2) and 2 were homozygotic (PlA2/A2).
In the control group, the frequency of the PlA2 allele was
17.7%: there were 15 heterozygotes (PlA1/A2) and 1 ho-
mozygote (PlA2/A2). The difference in PlA2 allelic frequency
between the groups was not significant.
Blood loss related to CABG was significantly greater (by
25%) in the aspirin group than in the control group (Figure
1). This was reflected by a significantly larger (137%)
volume of blood product transfusions required during post-
operative treatment of patients in the aspirin group (1.49 
1.41 units vs 0.76  1.77, aspirin vs control, P  .021).
When subjects were stratified accordingly to blood platelet
glycoprotein IIb/IIIa genotype, in the aspirin group PlA2
carriers had greater blood loss than PlA1 homozygotes (1858
 932 mL vs 1216  525 mL, P  .05). Interestingly, in
the control group, this relation was reversed (760  231 vs
1138  656 mL, P  .05). Thus in PlA1 homozygotes
postoperative blood loss was not affected by aspirin admin-
TABLE 1. Preoperative patient characteristics
Aspirin
group
Control
group
P
value
Sex (male/female) 45:6 42:9 .404
Age (y, mean  SD) 61.3 8.4 61.1  8.4 .879
Body mass index (kg/m2,
mean  SD)
6.4  3.1 27.0 2.9 .426
Hypertension (%) 66.7 56.9 .248
Diabetes (%) 17.6 19.6 .8
Left ventricular ejection
fraction (%)
55.1 8.4 55.7 8.4 .357
Left main stem disease (No.) 3 9 .124
Chronic obstructive
pulmonary disease (%)
5.9 3.9 .999
Renal insufficiency (%) 2 0.0 .999
Peripheral vascular
disease (%)
2 3.9 .999
History of stroke (%) 2 0 .999
New York Heart Association
class (mean  SD)
1.81 0.55 1.78 0.58 .5
Canadian Cardiovascular
Society class
(mean  SD)
3.3  0.4 3.3 0.5 .259
Patients with unstable
angina (No.)
10 8 .795
Platelet count (103 cells/
mm3, mean  SD)
222 208 187 202 .111istration, whereas in PlA2 carriers bleeding increased by
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After exclusion of the patients who underwent reexploration
for bleeding, blood loss and transfusion requirements re-
mained different between groups (Table 3).
Preoperative evaluation bleeding time (Simplate R) or
capillary occlusion time (PFA-100) failed to correlate with
postoperative bleeding. However, both Simplate and PFA-
100 measurements repeated immediately after CABG were
predictive of blood loss. Correlation between Simplate time
and blood loss was highly significant ( 0.201; P .005),
while PFA-100 closure time correlation with blood loss was
weaker (  0.152; P  .05 for epinephrine,   0.146; P
 .04 for adenosine diphosphate [ADP]). The platelet levels
dropped after CPB, but there were no differences between
groups at any time. Thereafter, platelet counts increased to
TABLE 2. Data related to CABG procedure
Aspirin
group
Control
group
P
value
CPB time (min, mean  SD) 87.0 24.1 85.6 21.0 .389
Aortic crossclamp time (min,
mean  SD)
46.9 19.0 48.8 13.0 .427
No. of grafts (mean  SD) 3.0 0.8 2.9 0.8 .354
Left internal thoracic artery
use (%)
82.3 80.4 .392
Inotropic support (excluding
dopamine) (%)
29.4 13.7 .045
IABP (%) 9.8 5.9 .713
CK-MB 12 postoperative h
(U/L, mean  SD)
62.2 51.5 52.5 40.5 .412
Troponin I 12 postoperative h
(ng/mL, mean  SD)
5.21 3.07 3.8 3.16 .322
Myocardial infarction (%) 3.9 3.9 .61
Reexploration for bleeding
(%)
7.8 3.9 .674
Wound infection (%) 3.9 0 .475
Prolonged assisted
ventilation (%)
3.9 0 .475
ICU stay (h, mean  SD) 37.8 54.1 24.7 3.8 .371
Hospital stay (d, mean  SD) 7.6 2.0 7.3 1.0 .378
Death (%) 3.9 2 .999
Blood loss (mL, mean  SD) 1281  598 1008 572 .018
Blood products transfused
(U, mean  SD)
1.49 1.41 0.76 1.77 .021
Platelet count first day after
CABG (103 cells/mm3,
mean  SD
137 39 139 43 .46
Platelet count third day after
CABG (103 cells/mm3,
mean  SD
260 74 289 94 .417
Platelets count seventh day
after CABG (103 cells/mm3,
mean  SD
398 109 411 80 .423260,000 and 289,000 cells/mm3 at day 3 and 399,000 and
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respectively; Figure 2). No postoperative differences in
CK-MB and troponin I levels were observed between the
groups.
Discussion
Recent American College of Cardiology and American
Heart Association Practice Guidelines updates for
CABG1 acknowledged that increased postoperative
bleeding and risk for reexploration associated with aspi-
rin are outweighed by the benefits of preoperative aspirin
use. The aim of study was to investigate whether a
common PlA1/A2 polymorphism, functionally associated
with anticlotting response to aspirin, could affect post-
operative risk for patients undergoing elective CABG.
The study was designed to evaluate preoperative and
postoperative hemostatic measures along with risk out-
comes in a series of aspirin-treated and control patients
undergoing CABG intervention. Genotyping of PlA1/A2
polymorphism was completed after patient recruitment
and after hospital discharge. Ex vivo studies on thrombin
generation14 had documented that PlA2 carriers were
more likely to be refractory to benefits of aspirin therapy.
The platelet arachidonic acid cyclooxygenase path-
way, which is irreversibly inhibited by aspirin, is one of
several mechanisms amplifying prothrombotic response
of these blood particles. During extracorporeal circula-
tion, shear stress is the overwhelming stimulus for plate-
let activation.15 It has been demonstrated that PlA2-pos-
itive platelets in healthy subjects present a
hyperresponsive status, manifested by increased glycop-
rotein IIb/IIIa fibrinogen binding and lower ADP activa-
tion threshold, resulting in increased adhesion, spreading,
aggregation, and clot retraction. Aspirin can impair
thrombin generation, which takes place on the surface of
activated platelets. Thus in the presence of aspirin, any
relevant variability caused by PlA1/A2 polymorphism
should be exposed during a surgical procedure character-
ized by massive platelet activation. Results of this study
TABLE 3. Data concerning blood loss and blood products
transfused after exclusion of patients undergoing reex-
ploration for bleeding
Aspirin
group
Control
group
P
value
Blood loss (mL, mean  SD) 1204 494 942 444 .008
Red blood packed cells
(U, mean  SD)
1.41 1.41 0.5 0.922 .0003
Fresh-frozen plasma
(U, mean  SD)
1.19 1.61 0.62 1.11 .028
Platelets (U, mean  SD) 0.39 0.65 0.08 0.35 .005confirm relatively low risk imposed by preoperative as-
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gotes, no excess bleeding or need for transfusions was
observed. Patients carrying the PlA2 allele, however, in
addition to a blunted response to aspirin in general, in the
particular case of CABG demonstrated a wide spectrum
of consequences related to a single amino acid substitu-
tion in IIIa integrin. Without aspirin, PlA2 carriers had
diminished blood loss, in agreement with the genetically
determined hyperresponsive status of their platelets. Un-The Journal of Thoraciexpectedly, preoperative aspirin increased blood loss in
the PlA2 group by 152%, indicating that cyclooxygenase
pathway plays important role in fine-tuning blood clot-
ting. It is possible that hyperreactive PlA2 platelets are
particularly sensitive to shear stress but without throm-
boxane generation cannot provide sufficient hemostasis.
An antiplatelet regimen achieved by concurrent use of
clopidogrel and aspirin resulted in additional protection
against acute vascular events in the Clopidogrel in Un-
Figure 1. Blood loss (in milliliters) in preop-
erative aspirin (ASA) and control groups. As-
terisks indicate mean. P  .015 between PlA1
homozygotes and PlA2 carriers in aspirin
group.
Figure 2. Platelet count (in cells per cubic
milliliter) in preoperative aspirin (ASA) and
control groups.c and Cardiovascular Surgery ● Volume 130, Number 3 795
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study.16 Perhaps this effective antiplatelet therapy of
cyclooxygenase inhibition and purine receptor blockade
can prevent platelets wear off during CABG, when con-
tinuous shear stress washes ADP out of platelets. In the
patients studied, the numbers of platelets before and after
CABG did not differ significantly. Thus the possibility of
bleeding related to thrombocytopenia could be excluded.
Further studies on platelet activation markers and ADP
platelet content during CABG should provide more in-
sight into this unfavorable pharmacogenetic interaction
between platelet PlA1/A2 polymorphism and risk imposed
by preoperative aspirin in patients undergoing CABG.
For PlA2 carriers receiving aspirin, one should consider
the use of special precautions to minimize bleeding ten-
dency after CABG. One of the possibilities is antithrom-
bolytic therapy (aprotinin, -aminocaproic acid) in this
group, which might be expected to effectively diminish
postoperative blood loss.17,18 Alternatively, hemostasis
could be secured through scheduled transfusion of fresh-
frozen plasma and platelet concentrate.
Limitations of the Study
The limited number of subjects studied did not allow us
to evaluate major adverse clinical events and major car-
diac and cerebral events. In fact, we observed only 3
deaths and 8 perioperative myocardial infarctions. Those
events did not correlate with discontinuation of aspirin in
patients operated on urgently; however this observation
lacks statistical power. The examined blood loss and
transfusion requirements could in fact be further divided
as simple end points. Because of the limited number of
PlA2 carriers in the study, we were not able to analyze
simple clinical end points.
Conclusions
PlA1 homozygotes normally had greater risk of perioper-
ative bleeding than PlA2 carriers. Capillary closure time
determined with the PFA-100 analyzer showed no advan-
tage relative to traditional bleeding time in predicting
postoperative blood loss. Aspirin pretreatment 12 and 3
hours before surgery revealed no beneficial effects and in
fact resulted in increased postoperative bleeding and
need for blood products transfusions. For patients posi-
tive for platelet PlA2 polymorphism receiving aspirin at
operation, special security measures should be consid-
ered, such as antifibrinolytic drugs or fresh-frozen plasma
or platelet concentrate transfusions.
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